MedTrace Logo

Non-Interventional Observational Retrospective Study to Evaluate Doravirine Based-regimens in HIV Infected Aged Patients (DORAge).

NCT05202613 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2022-01-21

No results posted yet for this study

Summary

The HIV-infected population is aging due to the success of combination antiretroviral therapy, which prolongs survival, as well as the growing number of newly diagnosed cases in adults 50 years old and over. This real-life, observational and retrospective study aims to evaluate the virological efficacy, toxicity and tolerability of Doravirine-based regimens in aged HIV-1 positive patients (\> 50 years), focusing on metabolic patterns and inflammation markers.

Conditions

Interventions

DRUG

Doravirine

Doravirine, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-04
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05202613 on ClinicalTrials.gov